Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) this morning announced that its wholly-owned U.S. subsidiary, Pivot Naturals LLC, (“PNL”), has entered a lease agreement for a manufacturing facility in Costa Mesa, California’s Measure “X” Zone. PNL will immediately submit applications to acquire a Marijuana Business Permit, Conditional Use Permit and Business License. Businesses that meet the requirements to operate in Costa Mesa’s Measure “X” Zone can establish research and development and testing laboratories and are permitted to conduct wholesale medical marijuana distributing, manufacturing, processing and transporting. The company intends to use the building as a state-of-the-art GMP manufacturing facility to begin producing its patented products to be marketed under the brand name ‘Pivot Naturals’. PNL will employ the company’s patented Ready To Infuse Cannabis (“RTIC”) method to convert high quality cannabis oil and isolates to powder for finished products such as capsules, stick packs and bulk additives for sale and distribution in the California market. Additionally, a section of the facility has been set aside to form production lines of topical creams and oral solutions utilizing the company’s other patented drug delivery technologies. “Securing a manufacturing facility in California is a major milestone for Pivot, enabling the company to generate revenue in 2018, in the largest cannabis market in the world,” Dr. Patrick Frankham, Pivot Pharmaeuticals CEO stated in the news release.
To view the full press release, visit http://nnw.fm/wn72R
About Pivot Pharmaceuticals Inc.
Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly owned medical cannabis products division, Pivot Green StreamHealth Solutions Inc. (“PGS”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has acquired worldwide rights to “RTIC” Ready-To-Infuse Cannabis powder to oil technology, BiPhasix™ Transdermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol, and tetrahydrocannabinol-based products. PGS’ initial product development candidates will include topical treatments for women’s sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. For more information, visit the company’s website at www.PivotPharma.com.
More from NetworkNewsBreaks
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]